-
Company Insights
NewVenmo – Competitor Profile
Founded in 2009, Venmo initially allowed users to send money via SMS. In late 2010, a Venmo app was launched. This was initially a payment service that focused on P2P payments and simple purchase transactions, such as payments to food trucks. Over the years, Venmo has expanded its use cases, allowing users to make payments to a wider range of merchants both online and offline via Venmo. Users can top up their accounts and link their app account to their...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Ovarian Cancer Drug Details: Livmoniplimab (ABBV-151) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Livmoniplimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Solid Tumor Drug Details: Livmoniplimab (ABBV-151) is under development...
-
New
Net Present Value Model: Terns Pharmaceuticals Inc’s TERN-501
Empower your strategies with our Net Present Value Model: Terns Pharmaceuticals Inc's TERN-501 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Non-Small Cell Lung Cancer Drug Details: Livmoniplimab...
-
Company Insights
NewC4Diagnostics SAS Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our C4Diagnostics SAS Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. C4Diagnostics SAS, is develops and commercializes IVD kits based on its proprietary, versatile, phenotypic and simple technology. The company is headquartered in France. GlobalData's Medical Devices company profile report, “C4Diagnostics SAS Pipeline Insight and Competitive Landscape, 2024" provides information about the company overview and analysis on their pipeline products. This company profile report provides key information and data related to:...
-
Company Insights
NewBioShai Ltd Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our BioShai Ltd Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. BioShai Ltd (BioShai) is a healthcare service provider that develops assays. The company concentrates on development of PDx assay for Parkinson's disease. It provides PDx which is a simple blood test used for the early diagnosis of Parkinson’s disease. Bioshai develops PDx based on the gene expression. BioShai’s gene expression is the measurement of the level of expression of a...
-
Sector Analysis
NewAngio Suites Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
The Angio Suites Market Report Overview The Angio Suites market size was $2.47 billion in 2023. Factors such as the betterment of healthcare facilities and an increasing number of diagnostic imaging centers will drive the market growth at a CAGR of more than 6% from 2023 to 2033. Angio Suites are multi-purpose examination rooms, where diverse angio/interventional procedures are performed. Angio Suites typically have an X-ray generator, an image intensifier (usually C-arms), and a tabletop that rotates to make it...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – Setrusumab in Osteogenesis Imperfecta
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Setrusumab in Osteogenesis Imperfecta report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Setrusumab in Osteogenesis Imperfecta Drug Details: Setrusumab is under development for...